	US 12,005,139 B2
	Ophthalmic formulations and related methods
Timothy R Willis, Raleigh, NC (US); and Ralph P. Stone, Fort Worth, TX (US)
Assigned to ETERNATEAR, INC., Raleigh, NC (US)
Filed by EternaTear, Inc., Raleigh, NC (US)
Filed on Jun. 8, 2023, as Appl. No. 18/207,339.
Application 18/207,339 is a continuation of application No. 17/689,212, filed on Mar. 8, 2022, granted, now 11,679,078.
Prior Publication US 2023/0310312 A1, Oct. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 47/24 (2006.01); A61K 47/44 (2017.01); A61P 27/04 (2006.01)

CPC A61K 9/0048 (2013.01) [A61K 9/1075 (2013.01); A61K 47/24 (2013.01); A61K 47/44 (2013.01); A61P 27/04 (2018.01)]

12 Claims

1. An ophthalmic suspension comprising

i) an aqueous phase comprising water and one or more components selected from the group consisting of at least one wax ester, at least one anionic polar surfactant, at least one nonionic surfactant, at least one salt, and at least one phosphate; and

ii) an oil phase comprising at least one mineral oil and, optionally, at least one wax ester,

wherein the ophthalmic suspension exhibits a Zeta potential of from about −60 mV to about −110 mV.